{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-041601","form_type":"8-K","ticker":"PYXS","cik":"0001782223","company_name":"Pyxis Oncology, Inc.","filed_at":"2023-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.212560+00:00","generated_at":"2026-06-11T14:56:47.846262+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Pyxis Oncology Q2 net loss $15.9M; cash $144.1M; Apexigen deal on track for August close","bullets":["Net loss $15.9M ($0.41/share) vs $25.6M ($0.79) in Q2 2022; loss narrowed on lower R&D and G&A.","Cash and short-term investments $144.1M as of June 30, 2023; expected runway into first half of 2025.","R&D expenses $11.4M (down from $17.2M YoY); G&A $6.7M (down from $8.6M YoY).","Third dose cohort initiated in Phase 1 trial of ADC PYX-201; three European sites recruiting.","Apexigen acquisition expected to close later in August 2023; sotigalimab development plan in Q4."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-041601","json":"https://secwatch.observer/filing/0000950170-23-041601.json","markdown":"https://secwatch.observer/filing/0000950170-23-041601.md","text":"https://secwatch.observer/filing/0000950170-23-041601.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782223/000095017023041601/0000950170-23-041601-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782223/000095017023041601/pyxs-20230811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T14:56:47.846262+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"257597cec5b4db501ec3f6a9fc5745a1a2d26837","claim":"Pyxis Oncology, Inc. reported the quarter ended June 30, 2023 results: net income $15.9 million, EPS $0.41 per common share.","evidence_excerpt":"Net loss was $15.9 million, or $0.41 per common share, for the three months ended June 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782223/000095017023041601/0000950170-23-041601-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Net income","value":"$15.9 million"},{"label":"EPS","value":"$0.41 per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}